Author:
Berglund Åke,Ullén Anders,Lisyanskaya Alla,Orlov Sergey,Hagberg Hans,Tholander Bengt,Lewensohn Rolf,Nygren Peter,Spira Jack,Harmenberg Johan,Jerling Markus,Alvfors Carina,Ringbom Magnus,Nordström Eva,Söderlind Karin,Gullbo Joachim
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference28 articles.
1. FDA (2011) Alkeran prescribing information NDA 14-691/S-029 and NDA 20-207/SLR-016
2. Falco P, Bringhen S, Avonto I, Gay F, Morabito F, Boccadoro M et al (2007) Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 7:945–957. doi: 10.1586/14737140.7.7.945
3. Piver MS (2006) Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy. Oncology (Williston Park) 20:1156–1158
4. Colvin M (1983) The alkylating agents. In: Chabner B (ed) The pharmacologic principles of cancer treatment. WB Saunders, Philadelphia, pp 276–308
5. Furner RL, Brown RK (1980) L-phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep 64:559–574
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献